Effect of recombinant human erythropoietin on mitomycin C-induced oxidative stress and genotoxicity in rat kidney and heart tissues

Human and Experimental Toxicology

Volumn 35, Issue 1, 2016, Pages 53-62

  Rjiba Touati, K ^a   Ayed Boussema, I ^a   Guedri, Y ^b   Achour, A ^b   Bacha, H ^a   Abid Essefi, S ^a  

^a Faculty of Dentistry   (Tunisia)

^b University Hospital of Sahloul   (Tunisia)

Author keywords

antigenotoxic effect; antioxidant effect; mitomycin C; rhEPO

Indexed keywords

CARBONYL DERIVATIVE; CATALASE; GLUTATHIONE; GLUTATHIONE DISULFIDE; MALONALDEHYDE; MITOMYCIN; RECOMBINANT ERYTHROPOIETIN; ALKYLATING AGENT; ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DNA DAMAGE; DNA FRAGMENTATION; DRUG EFFECT; ENZYME ACTIVITY; GENOTOXICITY; HEART; HEART PROTECTION; KIDNEY HOMOGENATE; LIPID PEROXIDATION; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENAL PROTECTION; SINGLE DRUG DOSE; TREATMENT DURATION; ANIMAL; CARDIAC MUSCLE; COMET ASSAY; DRUG ADMINISTRATION; DRUG EFFECTS; KIDNEY; MALE; METABOLISM; MUTAGEN TESTING; PROTEIN CARBONYLATION;

ALKYLATING AGENTS; ANIMALS; CATALASE; COMET ASSAY; DNA DAMAGE; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; GLUTATHIONE; HEART; KIDNEY; LIPID PEROXIDATION; MALE; MITOMYCIN; MUTAGENICITY TESTS; MYOCARDIUM; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RATS;

EID: 84951734274     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327115577521     Document Type: Article

References (57)

1. Gnad-Vogt SU, Hofheinz RD, Saussele S, et al. Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial. Anticancer Drugs 2005; 16: 435-440.
2. Cheung RY, Rauth AM, Yu W,. In vivo efficacy and toxicity of intratumorally delivered mitomycin C and its combination with doxorubicin using microsphere formulations. Anticancer Drugs 2005; 16: 423-433.
3. Bradner WT,. Mitomycin C: a clinical update. Cancer Treat Rev 2001; 27: 35-50.
4. Yeh ET,. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 2006; 57: 485-498.
5. Buzdar AU, Legha SS, Luna MA,. Pulmonary toxicity of mitomycin. Cancer 1980; 45: 236-244.
6. Lameire N, Kruse V, Rottey S,. Nephrotoxicity of anticancer drugs-an underestimated problem? Acta Clin Belg 2011; 66: 337-345.
7. Shiiki H, Dohi K, Nishioka H,. Glomerular tuft ballooning in mitomycin-C-induced renal impairment. Virchows Archiv A Pathol Anat Histopathol 1992; 420: 545-551.
8. Komiyama T, Kikuchi T, Sugiura Y,. Generation of hydroxyl radical by anticancer quinone drugs, carbazilquinone, mitomycin C, aclacinomycin A and adriamycin, in the presence of NADPH-cytochrome P-450 reductase. Biochem Pharmacol 1982; 31: 3651-3656.
9. Riggs CE,. Antitumor antibiotics and related compounds. In: Perry MC, (ed) The chemotherapy source book. Baltimore, MD: Williams & Wilkins, 1997, pp. 345-385.
10. Premkumar K, Pachiappan A, Abraham SK, et al. Effect of Spirulina fusiformis on cyclophosphamide and mitomycin-C induced genotoxicity and oxidative stress in mice. Fitoterapia 2001; 72: 906-911.
11. Turkez H, Aydin E, Aslan A,. Xanthoria elegans (Link) (lichen) extract counteracts DNA damage and oxidative stress of mitomycin C in human lymphocytes. Cytotechnology 2012; 64: 679-686.
12. Klaunig JE, Wang Z, Pu X, Zhou S,. Oxidative stress and oxidative damage in chemical carcinogenesis. Toxicol Appl Pharmacol 2011; 254: 86-99.
13. Wang Y, Gray JP, Mishin V, et al. Distinct roles of cytochrome P450 reductase in mitomycin C redox cycling and cytotoxicity. Mol Cancer Ther 2010; 9: 1852-1863.
14. Klaunig JE, Wang Z, Pu X, Zhou S,. Oxidative stress and oxidative damage in chemical carcinogenesis. Toxicol Appl Pharmacol 2011; 254: 86-99.
15. Freeman TA, Parvizi J, Della Valle CJ, Steinbeck MJ,. Reactive oxygen and nitrogen species induce protein and DNA modifications driving arthrofibrosis following total knee arthroplasty. Fibrogenesis Tissue Repair 2009; 2: 5.
16. Mazumdar M, Giri S, Giri A,. Role of quercetin on mitomycin C induced genotoxicity: analysis of micronucleus and chromosome aberrations in vivo. Mutat Res 2011; 721: 147-152.
17. Li F, Chong ZZ, Maiese K.,. Erythropoietin on a tightrope. Balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 2004; 13: 265-289.
18. Kuriyama S, Tomonari H, Yoshida H, et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-185.
19. Nemoto T, Yokota N, Keane WF, Rabb H,. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int 2001; 59: 246-251.
20. Hodges VM, Rainey S, Lappin TR, Maxwell AP,. Pathophysiology of anemia and erythrocytosis. Crit Rev Oncol Hematol 2007; 64: 139-158.
21. Chatterjee PK,. Pleiotropic renal actions of erythropoietin. Lancet 2005; 365: 1890-1892.
22. Liu X, Xie W, Liu P, et al. Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia reperfusion. Life Sci 2006; 78: 2255-2264.
23. Okada T, Sawada T, Kubota K,. Asialoerythropoietin has strong renoprotective effects against ischemia reperfusion injury in a murine model. Transplantation 2007; 84: 504-510.
24. Riksen NP, Hausenloy DJ, Yellon D,. Erythropoietin: ready for prime-time cardioprotection. A review. Trends Pharmacol Sci 2008; 29: 258-267.
25. Ishii Y, Sawada T, Murakani T, et al. Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a non-human primate model. Nephrol Dial Transplant 2010; 26: 1157-1162.
26. Chateauvieux S, Grigorakaki C, Morceau F, Dicato M, Diederich M,. Erythropoietin, erythropoiesis and beyond. Biochem Pharmacol 2011; 82: 1291-1303.
27. Bradford MM,. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
28. Mercier Y, Gatellier P, Renerre M,. Lipid and protein oxidation in vitro, and antioxidant potential in meat from Charolais cows finished on pasture or mixed diet. Meat Sci 2004; 66: 467-473.
29. Aust SD, Morehouse LA, Thomas CEJ,. Role of metals in oxygen radical reactions. Free Radic Biol Med 1985; 1: 3-25.
30. Tietze F,. Enzimatic method for quantitative determination of nanogram amounts of total and oxidized gluthathione: applications to mammalian blood and others tissues. Anal Biochem 1969; 27: 502-522.
31. Clairbone A,. Catalase activity. Handbook of methods for oxygen radical research. Boca Raton, FL: CRC Press, 1985, pp. 283-284.
32. Tice RR, Aqurell E, Anderson D, et al. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000; 35: 206-221.
33. Picada JN, Flores DG, Zettler CG, et al. DNA damage in brain cells of mice treated with an oxidized form of apomorphine. Brain Res Mol Brain Res 2003; 114: 80-85.
34. Banath JP, Kim A, Olive P,. Overnight lysis improves the efficiency of DNA damage detection in the alkaline comet assay. Radiat Res 2002; 1155: 564-571.
35. Collins AR, Dusinska M, Gedik CM, Stetina R,. Oxidative damage to DNA: do we have a reliable biomarker? Environ Health Perspect 1996; 104: 465-469.
36. Draper HH, Squires EJ, Mahmoodi H, et al. A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials. Free Radic Biol Med 1993; 15: 353-363.
37. Kim YH, Mun KC, Lee SS,. Oxidative damage in renal transplant patients. Transplant Proc 2000; 32: 1777-1778.
38. Dotan Y, Lichtenberg D, Pinchuk I,. Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Prog Lipid Res 2004; 43: 200-227.
39. Verweij J, Funke-Kupper AJ, Teule GJ,. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med Oncol Tumor Pharmacother 1988; 5: 159-163.
40. Wen MC, Chen CH, Ho WL,. Mitomycin c-induced renal insufficiency. A case report. J Med Sci 2003; 19: 317-321.
41. Panjrath GS, Jain D,. Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging: a review. J Nucl Cardiol 2006; 13: 415-426.
42. Naughton CA,. Drug-induced nephrotoxicity: a review. Am Fam Physicians 2008; 78: 743-750.
43. Senkus E, Jassem J,. Complications of treatment cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011; 37: 300-311.
44. Siddique YH, Ara G, Beg T, et al. Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and curcumin in cultured human blood lymphocytes. Exp Toxicol Pathol 2010; 62: 503-508.
45. Solaroglu I, Solaroglu A, Kaptanoglu E, et al. Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain. Childs Nerv Syst 2003; 19: 19-22.
46. Kumral A, Baskin H, Gokmen N, et al. Selective inhibition of nitric oxide in hypoxic-ischemic brain model in newborn rats: is it an explanation for the protective role of erythropoietin? Biol Neonate 2004; 85: 51-54.
47. Mazumdar M, Giri S, Giri A,. Role of quercetin on mitomycin C induced genotoxicity: analysis of micronucleus and chromosome aberrations in vivo. Mut Res 2011; 721: 147-152.
48. Yang CW, Li C, Jung JY, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 2003; 10: 1096-1191.
49. Mihov D, Bogdanov N, Grenacher B, et al. Erythropoietin protects from reperfusion-induced myocardial injury by enhancing coronary endothelial nitric oxide production. Eur J Cardiothorac Surg 2009; 35: 839-846.
50. Johnson DW, Vesey DA, Gobe GC,. Erythropoietin protects against acute kidney injury and failure. Open Drug Discov J 2010; 2: 8-17.
51. Dalle-Donne I, Giustarini D, Colombo R, et al. Protein carbonylation in human diseases. Trends Mol Med 2003; 9: 169-176.
52. Dalle-Donne I, Rossi R, Giustarini D, et al. Protein carbonyl groups as biomarkers of oxidative damage in human disease. Clin Chim Acta 2003; 329: 23-38.
53. Meister A, Anderson ME,. Glutathione. Annu Rev Biochem 1983; 52: 711-760.
54. 2+-ADP and the relative unimportance of OH in the mechanism of mitomycin C-induced lipid peroxidation. Biochim Biophys Acta 1984; 796: 285-293.
55. Pagano G,. Mitomycin C and diepoxybutane action mechanisms and FANCC protein functions: further insights into the role for oxidative stress in Fanconi's anaemia phenotype. Carcinogenesis 2000; 21: 1067-1068.
56. Singh N, McCoy M, Tice R, Schneider E,. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988; 175: 184-191.
57. Sun Y, Zhou C, Polk P, et al. Mechanisms of erythropoietin-induced brain protection in neonatal hypoxia ischemia rat model. J Cereb Blood Flow Metab 2004; 24: 259-270.